Pfizer Reports FDA Gives Priority Review To Myeloid Leukemia Treatment

Pfizer Reports FDA Gives Priority Review To Myeloid Leukemia Treatment

Pfizer (PFE) and the private Avillion reported Tuesday a supplemental new drug application for bosutinib, a drug to treat certain types of myeloid leukemia, has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). Pfizer said that if approved, the new application would expand the approved use of bosutinib to include patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukemia. Pfizer […]

Read More ˃
ImmunoGen Shares Add 12% Pre-Bell Drug Development Deal Worth at Least $175 Mln With Jazz Pharma

ImmunoGen Shares Add 12% Pre-Bell Drug Development Deal Worth at Least $175 Mln With Jazz Pharma

ImmunoGen (IMGN) shares rose 8% in pre-market trade after the company struck a deal worth at least $175 million with Jazz Pharmaceuticals (JAZZ) to develop and commercialize antibody-drug conjugate (ADC) products. Jazz will pay ImmunoGen an upfront payment of $75 million and up to $100 million in development funding over seven years to support the ADC programs. Also, Jazz may exercise its opt-in right at any time prior to a […]

Read More ˃